ArticleMolecular psychiatry2026
Trends and patterns of medical stimulant use by US adults.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The authors describe trends in stimulant prescribing to US adults and characterize stimulant-treated adults by use of three modalities: telehealth only, in-person only, or mixed (hybrid) behavioral healthcare. Among US adults in the 2018-2023 Medical Expenditure Panel Survey (n = 119,138), annual stimulant treatment rates are presented with age- and sex-adjusted marginal 2018-2023 differences across sociodemographic and clinical strata. Characteristics of stimulant-treated adults are also presented by reason for stimulant use (attention-deficit/hyperactivity disorder vs. other) and behavioral healthcare modality. Between 2018 and 2023, medical stimulant use increased from 1.8% to 2.2% of adults, including greater increases for adults with household incomes >400% than <100% of the Federal Poverty Level and employed adults than non-employed adults over age 65. However, the percentage of patients receiving ADHD visits who were treated with stimulants declined from 81.6% in 2018 to 74.6% in 2023. In 2021-2023, 48.4% of stimulant-treated patients received all their behavioral healthcare as in-person visits rather than hybrid (30.9%) or telehealth only (20.7%). These three groups did not differ in the percentage who received stimulants for ADHD, the number of stimulant prescriptions they received, or benzodiazepine or opioid prescriptions. In summary, between 2018 and 2023, adult stimulant use increased, particularly among higher-income and employed adults, while the share of ADHD patients treated with stimulants declined. Approximately one-half of stimulant-treated patients received teletherapy, and service modality was not related to ADHD treatment, stimulant prescription counts, or benzodiazepine or opioid prescriptions.
Indexed as
Identifiers
41731001What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.